


## PHARMACEUTICAL 2023



## Checkpoint Therapeutics Inc. Rank 433 of 446





## PHARMACEUTICAL 2023



## Checkpoint Therapeutics Inc. Rank 433 of 446

The relative strengths and weaknesses of Checkpoint Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Checkpoint Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Checkpoint Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 252% points.

The company's Economic Capital Ratio, given in the ranking table, is -417%, being 461% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	13,290
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	32,773
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-4,291
Other Revenues	192
Property and Equipment	0
Research and Development	49,825
Selling, General and Administrative Expense	8,700

Output Variable	Value in 1000 USD
Assets	13,290
Liabilities	32,773
Expenses	58,525
Revenues	192
Stockholders Equity	-19,483
Net Income	-62,624
Comprehensive Net Income	-62,624
Economic Capital Ratio	-417%